Infertility Drugs Market Size, Share & Trends Analysis Report By Drug Class (Gonadotropins, Aromatase Inhibitors, SERMs, Dopamine Agonists) By End-user (Men, Women), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030

Infertility Drugs Market Size, Share & Trends Analysis Report By Drug Class (Gonadotropins, Aromatase Inhibitors, SERMs, Dopamine Agonists) By End-user (Men, Women), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030

Infertility Drugs Market Growth & Trends

The global infertility drugs market size is expected to reach USD 5.6 billion by 2030 expanding at a CAGR of 6.1% from 2023 to 2030 according to a new report by Grand View Research, Inc. The market seems to be saturated with fewer opportunities for new entrants. The companies including Merck & Co. Inc., Ferring B.V., and Organon group of companies holds majority of market share. Thus, the pharmaceutical companies are focusing on developing biosimilar of gonadotropins for market penetration. For instance, Qilu Pharmaceutical Co., Ltd. focuses on developing QL1012, a recombinant human follicle stimulating hormone which is under phase 3 clinical trial. Successful completion of of trial and subsequent launch is anticipated to drive market.

Increasing initiatives undertaken by public and private organizations to support patients living with infertility are expected to positively contribute to infertility treatment market growth. For instance, in March 2022, the French government introduced new IVF law under which single women and same sex-couple avail treatment free of cost under the country’s national healthcare system.

In addition, in November 2022, Saudi Arabia’s Health Insurance Council conducted studies with regard to the inclusion of medicines under medical insurance coverage. The successful completion of the study and inclusion of medication under insurance is anticipated to increase patient access to treatment, subsequently, increase demand for medicines over the forecast period.

Rising awareness about disease and its available medicines among patients and physicians is anticipated to increase the target population for the market. For instance, in September 2021, Mubadala Health and United Eastern Medical Services (UEMedical) organized the ‘3rd HealthPlus Middle East Fertility Conference with an aim to rise awareness about the advancements in the treatment of this conditions and its benefits among physicians and patients in Dubai.

Moreover, there are several initiatives undertaken by the national government worldwide to tackle low fertility rate issues and promote childbirth which may increase the demand for drugs. For instance, in August 2022, the South Korean Government announced a provision for a monthly allowance of USD 740 per new child born in the family with an aim to tackle the low fertility rate in the country and encourage childbirth.

Infertility Drugs Market Report Highlights

  • By drug class, the gonadotropin segment accounted for the largest share of the market in 2022 and is anticipated to witness fastest growth over the forecast period. This can be attributed to the availability of FDA-approved gonadotropins for infertility conditions in the market
  • Based on end-user, the women segment dominated the infertility drugs market in 2022 owing to the rising incidence of the diseases such as PCOS, HPV associated vaginal cancer, uterine fibroids in women. As per the cohort studies published, in April 2022, approximately 1.5% of all French women aged 20 to 49 years were diagnosed with this condition annually.
  • Hospiatal pharmacy segment dominated the infertility drugs market in 2022. This growth can be attributed to an increase in inpatient visits for the diagnosis and consulation of this condition worldwide
  • North America dominated the global market in 2022 owing to factors such as high awareness among healthcare professionals about infertility conditions, ease of availability of drugs, and an increase in disease prevalence.
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation and Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2
1.10.3 Objective 3
1.10.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Snapshot
Chapter 3 Infertility Drugs: Market Variables, Trends, and Scope
3.1 Market Lineage Outlook
3.1.1 Women's Health Market
3.2 Penetration and Growth Prospect Mapping
3.3 Regulatory Landscape
3.4 Market Dynamics
3.5 Market Driver Analysis
3.5.1 Rising burden of infertility
3.5.2 Presence of strong product pipeline
3.5.3 Increasing funding for infertility R&D
3.6 Market Restraint Analysis
3.6.1. Unsupportive Government Regulations for Infertility Drugs
3.7 PESTEL Analysis
3.8 Industry Analysis-Porter’s Five Forces
3.9 Pipeline Analysis
Chapter 4 Infertility Drugs Market: Segment Analysis, by Drug Class, 2018 - 2030 (USD Million)
4.1 Infertility Drugs Market: Drug Class Movement Analysis
4.2 Gonadotropins
4.2.1 Gonadotropins Market, 2018 - 2030 (USD Million)
4.2.2 Aromatase Inhibitors
4.2.2.1 Aromatase Inhibitors Market, 2018 - 2030 (USD Million)
4.2.3 Selective Estrogen Receptor Modulators (SERMs)
4.2.3.1 Selective Estrogen Receptor Modulators (SERMs) Market, 2018 - 2030 (USD Million)
4.2.4 Dopamine Agonists
4.2.4.1 Dopamine Agonists Market, 2018 - 2030 (USD Million)
4.2.5 Others
4.2.5.1 Others Market, 2018 - 2030 (USD Million)
Chapter 5 Infertility Drugs Market: Segment Analysis, by Distribution Channel, 2018 - 2030 (USD Million)
5.1 Infertility Drugs Market: Distribution Channel Movement Analysis
5.2 Hospital Pharmacy
5.2.1 Hospital Pharmacy Market, 2018 - 2030 (USD Million)
5.3 Specialty & Retail Pharmacy
5.3.1 Specialty & Retail Pharmacy Market, 2018 - 2030 (USD Million)
5.4 Online Pharmacy
5.4.1 Online Pharmacy Market, 2018 - 2030 (USD Million)
Chapter 6 Infertility Drugs Market: Segment Analysis, by End-User, 2018 - 2030 (USD Million)
6.1 Infertility Drugs Market: End-User Movement Analysis
6.2 Men
6.2.1 Men Market, 2018 - 2030 (USD Million)
6.3 Women
6.3.1 Women Market, 2018 - 2030 (USD Million)
Chapter 7 Infertility Drugs Market: Regional Estimates and Trend Analysis
7.1 North America
7.1.1 SWOT Analysis:
7.1.1.1 North America Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.1.2 U.S.
7.1.2.1 Key Country Dynamics
7.1.2.2 Target Disease Prevalence
7.1.2.3 Competitive Scenario
7.1.2.4 Regulatory Framework
7.1.2.5 Reimbursement Scenario
7.1.2.6 U.S. Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.1.3 Canada
7.1.3.1 Key Country Dynamics
7.1.3.2 Target Disease Prevalence
7.1.3.3 Competitive Scenario
7.1.3.4 Regulatory Framework
7.1.3.5 Reimbursement Scenario
7.1.3.6 Canada Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2 Europe
7.2.1 SWOT Analysis:
7.2.1.1 Europe Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.2 UK
7.2.2.1 Key Country Dynamics
7.2.2.2 Target Disease Prevalence
7.2.2.3 Competitive Scenario
7.2.2.4 Regulatory Framework
7.2.2.5 Reimbursement Scenario
7.2.2.6 Prescription and Dispensing Scenario
7.2.2.7 UK Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.3 Germany
7.2.3.1 Key Country Dynamics
7.2.3.2 Target Disease Prevalence
7.2.3.3 Competitive Scenario
7.2.3.4 Regulatory Framework
7.2.3.5 Reimbursement Scenario
7.2.3.6 Germany Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.4 France
7.2.4.1 Key Country Dynamics
7.2.4.2 Target Disease Prevalence
7.2.4.3 Competitive Scenario
7.2.4.4 Regulatory Framework
7.2.4.5 Reimbursement Scenario
7.2.4.6 France Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.5 Italy
7.2.5.1 Key Country Dynamics
7.2.5.2 Target Disease Prevalence
7.2.5.3 Competitive Scenario
7.2.5.4 Regulatory Framework
7.2.5.5 Reimbursement Scenario
7.2.5.6 Italy Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.6 Spain
7.2.6.1 Key Country Dynamics
7.2.6.2 Target Disease Prevalence
7.2.6.3 Competitive Scenario
7.2.6.4 Regulatory Framework
7.2.6.5 Reimbursement Scenario
7.2.6.6 Spain Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.7 Denmark
7.2.7.1 Key Country Dynamics
7.2.7.2 Target Disease Prevalence
7.2.7.3 Competitive Scenario
7.2.7.4 Regulatory Framework
7.2.7.5 Reimbursement Scenario
7.2.7.6 Denmark Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.8 Sweden
7.2.8.1 Key Country Dynamics
7.2.8.2 Target Disease Prevalence
7.2.8.3 Competitive Scenario
7.2.8.4 Regulatory Framework
7.2.8.5 Reimbursement Scenario
7.2.8.6 Sweden Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.9 Norway
7.2.9.1 Key Country Dynamics
7.2.9.2 Target Disease Prevalence
7.2.9.3 Competitive Scenario
7.2.9.4 Regulatory Framework
7.2.9.5 Reimbursement Scenario
7.2.9.6 Norway Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.9 Rest of Europe Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Asia Pacific
7.3.1 SWOT Analysis:
7.3.1.1 Asia Pacific Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2 Japan
7.3.2.1 Key Country Dynamics
7.3.2.2 Target Disease Prevalence
7.3.2.3 Competitive Scenario
7.3.2.4 Regulatory Framework
7.3.2.5 Reimbursement Scenario
7.3.2.6 Prescription and Dispensing Scenario
7.3.2.7 Japan Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.3 China
7.3.3.1 Key Country Dynamics
7.3.3.2 Target Disease Prevalence
7.3.3.3 Competitive Scenario
7.3.3.4 Regulatory Framework
7.3.3.5 Reimbursement Scenario
7.3.3.6 China Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.4 India
7.3.4.1 Key Country Dynamics
7.3.4.2 Target Disease Prevalence
7.3.4.3 Competitive Scenario
7.3.4.4 Regulatory Framework
7.3.4.5 Reimbursement Scenario
7.3.4.6 India Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.5 Australia
7.3.5.1 Key Country Dynamics
7.3.5.2 Target Disease Prevalence
7.3.5.3 Competitive Scenario
7.3.5.4 Regulatory Framework
7.3.5.5 Reimbursement Scenario
7.3.5.6 Australia Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.6 South Korea
7.3.6.1 Key Country Dynamics
7.3.6.2 Target Disease Prevalence
7.3.6.3 Competitive Scenario
7.3.6.4 Regulatory Framework
7.3.6.5 Reimbursement Scenario
7.3.6.6 South Korea Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.7 Thailand
7.3.7.1 Key Country Dynamics
7.3.7.2 Target Disease Prevalence
7.3.7.3 Competitive Scenario
7.3.7.4 Regulatory Framework
7.3.7.5 Reimbursement Scenario
7.3.7.6 Thailand Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.8 Rest of APAC Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Latin America
7.4.1 SWOT Analysis:
7.4.1.1 Latin America Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.2 Brazil
7.4.2.1 Key Country Dynamics
7.4.2.2 Target Disease Prevalence
7.4.2.3 Competitive Scenario
7.4.2.4 Regulatory Framework
7.4.2.5 Reimbursement Scenario
7.4.2.6 Prescription and Dispensing Scenario
7.4.2.7 Brazil Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.3 Mexico
7.4.3.1 Key Country Dynamics
7.4.3.2 Target Disease Prevalence
7.4.3.3 Competitive Scenario
7.4.3.4 Regulatory Framework
7.4.3.5 Reimbursement Scenario
7.4.3.6 Mexico Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4 Argentina
7.4.4.1 Key Country Dynamics
7.4.4.2 Target Disease Prevalence
7.4.4.3 Competitive Scenario
7.4.4.4 Regulatory Framework
7.4.4.5 Reimbursement Scenario
7.4.4.6 Argentina Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.5. Rest of Latin America Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Middle East & Africa (MEA)
7.5.1 SWOT Analysis:
7.5.1.1 MEA Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2 South Africa
7.5.2.1 Key Country Dynamics
7.5.2.2 Target Disease Prevalence
7.5.2.3 Competitive Scenario
7.5.2.4 Regulatory Framework
7.5.2.5 Reimbursement Scenario
7.5.2.6 Prescription and Dispensing Scenario
7.5.2.7 South Africa Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.3 Saudi Arabia
7.5.3.1 Key Country Dynamics
7.5.3.2 Target Disease Prevalence
7.5.3.3 Competitive Scenario
7.5.3.4 Regulatory Framework
7.5.3.5 Reimbursement Scenario
7.5.3.6 Saudi Arabia Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.4 UAE
7.5.4.1 Key Country Dynamics
7.5.4.2 Target Disease Prevalence
7.5.4.3 Competitive Scenario
7.5.4.4 Regulatory Framework
7.5.4.5 Reimbursement Scenario
7.5.4.6 UAE Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.5 Kuwait
7.5.5.1 Key Country Dynamics
7.5.5.2 Target Disease Prevalence
7.5.5.3 Competitive Scenario
7.5.5.4 Regulatory Framework
7.5.5.5 Reimbursement Scenario
7.5.5.6 Kuwait Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.6 Rest of MEA Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8 Infertility Drugs Market: Competitive Analysis
8.1 Recent Developments & Impact Analysis, by Key Market Participants
8.1.1 New Product Launch
8.1.2 Merger and Acquisition
8.1.3 Licensing Agreements
8.1.4 Conferences and Campaigns
8.2 Company Categorization
8.2.1 Innovators
8.2.2 Market Leaders
8.3 Vendor Landscape
8.3.1 List of Key Distributors and Channel Partners
8.3.2 Key Customers
8.4 Public Companies
8.4.1 Key Company Market Share Analysis, 2021
8.4.2 Company Market Position Analysis
8.4.3 Heat Map Analysis
8.4.4 Competitive Dashboard Analysis
8.4.4.1 Market Differentiators
8.5 Private Companies
8.5.1 List of Key Emerging Companies
8.5.2 Regional Network Map
8.6 Company Profiles
8.6.1.Bayer AG
8.6.1.1 Company Overview
8.6.1.2 Financial Performance
8.6.1.3 Product Benchmarking
8.6.1.4 Strategic Initiatives
8.6.2 Novartis AG
8.6.2.1 Company Overview
8.6.2.2 Financial Performance
8.6.2.3 Product Benchmarking
8.6.2.4 Strategic Initiatives
8.6.3 Merck & Co., Inc.
8.6.3.1 Company Overview
8.6.3.2 Financial Performance
8.6.3.3 Product Benchmarking
8.6.3.4 Strategic Initiatives
8.6.4 Ferring B.V.
8.6.4.1 Company Overview
8.6.4.2 Financial Performance
8.6.4.3 Product Benchmarking
8.6.4.4 Strategic Initiatives
8.6.5 Pfizer Inc.
8.6.5.1 Company Overview
8.6.5.2 Financial Performance
8.6.5.3 Product Benchmarking
8.6.5.4 Strategic Initiatives
8.6.6 Mankind Pharma
8.6.6.1 Company Overview
8.6.6.2 Financial Performance
8.6.6.3 Product Benchmarking
8.6.6.4 Strategic Initiatives
8.6.7 Teva Pharmaceutical Industries LTD.
8.6.7.1 Company Overview
8.6.7.2 Financial Performance
8.6.7.3 Product Benchmarking
8.6.7.4 Strategic Initiatives
8.6.8 Sanofi
8.6.8.1 Company Overview
8.6.8.2 Financial Performance
8.6.8.3 Product Benchmarking
8.6.8.4 Strategic Initiatives
8.6.9 Abbott
8.6.8.1 Company Overview
8.6.9.2 Financial Performance
8.6.9.3 Product Benchmarking
8.6.9.4 Strategic Initiatives
8.6.10 Organon Group of Countries
8.6.10.1 Company Overview
8.6.10.2 Product Benchmarking
8.6.10.3 Strategic Initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings